Aytu BioPharma earnings beat by $0.14, revenue topped estimates
Aytu BioPharma (AYTU) reported Q1 EPS of -$0.20, beating estimates by $0.14, with revenue at $14.84M, exceeding expectations of $12.66M. The stock is down 20.18% over 3 months and 8.08% over 12 months. InvestingPro rates its financial health as 'good performance'.

